What is the Market's View on Predictive Oncology Inc (POAI) Stock's Price and Volume Trends Wednesday?

Overall market sentiment has been high on Predictive Oncology Inc (POAI) stock lately. POAI receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator.

Predictive Oncology Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on POAI!

See Full POAI Report

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With POAI Stock Today?

Predictive Oncology Inc (POAI) stock is trading at $6.10 as of 10:40 AM on Wednesday, Jul 12, a gain of $0.50, or 8.93% from the previous closing price of $5.60. The stock has traded between $5.65 and $6.22 so far today. Volume today is less active than usual. So far 80,080 shares have traded compared to average volume of 164,671 shares.

More About Predictive Oncology Inc

Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Helomics, zPREDICTA, Soluble and Skyline. It derives prime revenue from the Skyline segment which consists of the STREAMWAY System product sales, and TumorGenesis subsidiary (Research and Development) is included within corporate. The STREAMWAY System virtually eliminates staff exposure to blood, irrigation fluid, and other potentially infectious fluids found in the healthcare environment. Its Helomics division is focused on improving the effectiveness of cancer therapy using proprietary, multi-omic tumor profiling platform, a one-of-a-kind database of historical tumor data, and the power of AI to build predictive models of tumor drug response. Click Here to get the full Stock Report for Predictive Oncology Inc stock.